Literature DB >> 9740267

Serum cortisol levels in patients with uncomplicated and cerebral malaria.

T Shwe1, M Khin, H Min, K K Hla, Y Y Win, K Htwe, T M Thu.   

Abstract

Ten patients with uncomplicated malaria, ten with cerebral malaria and 37 controls (blood donors from blood bank) were included in the study. The serum cortisol levels of the patients were determined daily for 7 days while they were at the hospital. A radio-immunoassay method was used for quantitative measurement of cortisol in human serum. The mean serum cortisol level of patients with uncomplicated malaria was 528.2 +/- 123.9 nmol/l, with cerebral malaria was 516.0 +/- 80.5 nmol/l, and in controls was 393.8 +/- 141.0 nmol/l. There was a significant rise of serum cortisol levels in patients with malaria when compared to controls at the day of admission to hospital. There was no significant difference between uncomplicated malaria patients and those with cerebral malaria. There was also no significant difference between the different days of treatment up till day 7. We found no cortisol insufficiency in cases with falciparum malaria during acute and convalescent stages of illness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740267

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  2 in total

1.  Towards Improving Point-of-Care Diagnosis of Non-malaria Febrile Illness: A Metabolomics Approach.

Authors:  Saskia Decuypere; Jessica Maltha; Stijn Deborggraeve; Nicholas J W Rattray; Guiraud Issa; Kaboré Bérenger; Palpouguini Lompo; Marc C Tahita; Thusitha Ruspasinghe; Malcolm McConville; Royston Goodacre; Halidou Tinto; Jan Jacobs; Jonathan R Carapetis
Journal:  PLoS Negl Trop Dis       Date:  2016-03-04

2.  11β-hydroxysteroid dehydrogenase type 1 has no effect on survival during experimental malaria but affects parasitemia in a parasite strain-specific manner.

Authors:  L Vandermosten; C De Geest; S Knoops; G Thijs; K E Chapman; K De Bosscher; G Opdenakker; P E Van den Steen
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.